BMRN Stock Overview
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
BioMarin Pharmaceutical Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$83.81 |
52 Week High | US$100.38 |
52 Week Low | US$76.02 |
Beta | 0.31 |
1 Month Change | -5.59% |
3 Month Change | -13.19% |
1 Year Change | -9.24% |
3 Year Change | 6.74% |
5 Year Change | -5.35% |
Change since IPO | 538.55% |
Recent News & Updates
Recent updates
BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin: A Good Anchor For Your Biotech Portfolio
May 10BioMarin: Keep Waiting For The Growth
Mar 03BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?
Feb 24BioMarin's Win In Phase 3 Hemophilia Study Makes Its Investment Case Stronger
Jan 11BioMarin: Voxzogo Approval Could Trigger A Lengthy Bull Run For Cash Rich Biotech
Nov 01Shareholder Returns
BMRN | US Biotechs | US Market | |
---|---|---|---|
7D | -2.5% | -2.1% | 0.5% |
1Y | -9.2% | 9.7% | 29.0% |
Return vs Industry: BMRN underperformed the US Biotechs industry which returned 9.7% over the past year.
Return vs Market: BMRN underperformed the US Market which returned 29% over the past year.
Price Volatility
BMRN volatility | |
---|---|
BMRN Average Weekly Movement | 3.2% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BMRN has not had significant price volatility in the past 3 months.
Volatility Over Time: BMRN's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 3,401 | Alexander Hardy | https://www.biomarin.com |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company’s commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase.
BioMarin Pharmaceutical Inc. Fundamentals Summary
BMRN fundamental statistics | |
---|---|
Market cap | US$15.81b |
Earnings (TTM) | US$167.65m |
Revenue (TTM) | US$2.42b |
94.3x
P/E Ratio6.5x
P/S RatioIs BMRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BMRN income statement (TTM) | |
---|---|
Revenue | US$2.42b |
Cost of Revenue | US$1.26b |
Gross Profit | US$1.16b |
Other Expenses | US$989.95m |
Earnings | US$167.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.89 |
Gross Margin | 47.85% |
Net Profit Margin | 6.93% |
Debt/Equity Ratio | 22.0% |
How did BMRN perform over the long term?
See historical performance and comparison